Health care stocks were advancing premarket Monday, with The Health Care Select Sector SPDR Fund (XLV) up 0.1% and the iShares Biotechnology ETF (IBB) 0.3% higher.
Novartis (NVS) will keep manufacturing treatments for malaria and leprosy even if regular orders stop due to global health funding cuts, Reuters reported, citing its global health president. The company's shares were down more than 2% pre-bell.
ImmunityBio (IBRX) stock was up more than 4% after the company reported a narrower Q1 net loss as revenue increased during the period.
Dr. Reddy's Laboratories (RDY) shares were up past 3% after the company posted higher fiscal Q4 earnings and revenue.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。